GordanaVlahovicMD

Oncology • Durham, NC

Assistant Professor, Medicine, Duke University School of Medicine

Join to view full profile

Dr. Vlahovic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vlahovic's full profile

Already have an account?

Office
40 Duke Medicine Cir
Durham, NC 27710
Phone+1 919-684-8111

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2000 - 2003
Duke University HospitalResidency, Internal Medicine, 1997 - 2000
University of Zagreb Faculty of MedicineClass of 1987

Certifications & Licensure

NC State Medical License 2001 - 2022

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer Start of enrollment: 2007 May 01
Terminated
Phase 2
Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia Start of enrollment: 2007 Apr 24
Completed
Phase 1
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2006 Feb 06
Completed
Phase 1
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2007 Sep 01
Completed
Phase 2
Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer Start of enrollment: 2008 Sep 01
Completed
Phase 1
Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme Start of enrollment: 2009 Sep 01
Completed
Phase 1
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma Start of enrollment: 2014 Jan 09
Terminated
Phase 1, Phase 2
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07
Active, not recruiting
Phase 3
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 Start of enrollment: 2004 Nov 01
Terminated
Phase 1, Phase 2
IDH1 Peptide Vaccine for Recurrent Grade II Glioma Start of enrollment: 2016 Jan 28
Completed
Phase 1
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Start of enrollment: 2015 Jan 01
Completed
Phase 1, Phase 2
EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma Start of enrollment: 2017 Feb 01
Terminated
Phase 1
PVSRIPO in Recurrent Malignant Glioma Start of enrollment: 2017 Jun 01
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

418 citations
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Eileen M. O'Reilly, Do Youn Oh, Neesha C. Dhani, Daniel J. Renouf, Myung Ah Lee
JAMA Oncology. 2019-10-01
19 citations
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.
Yutaka Fujiwara, Haruo Iguchi, Noboru Yamamoto, Manabu Hayama, Masahiro Nii
Cancer Science. 2019-05-01
23 citations
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
Mary Lou Affronti, Jennifer G. Jackman, Frances McSherry, James E. Herndon, Elwood C. Massey
The Oncologist. 2018-08-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member